Personalis/$PSNL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Personalis
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Ticker
$PSNL
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
229
ISIN
US71535D1063
Website
Personalis Metrics
BasicAdvanced
$577M
-
-$1.23
1.87
-
Price and volume
Market cap
$577M
Beta
1.87
52-week high
$7.20
52-week low
$1.14
Average daily volume
837K
Financial strength
Current ratio
6.906
Quick ratio
6.579
Long term debt to equity
16.841
Total debt to equity
21.812
Interest coverage (TTM)
-1,560.07%
Profitability
EBITDA (TTM)
-56.392
Gross margin (TTM)
33.30%
Net profit margin (TTM)
-98.10%
Operating margin (TTM)
-78.28%
Effective tax rate (TTM)
-0.02%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
-17.90%
Return on equity (TTM)
-51.25%
Valuation
Price to revenue (TTM)
5.216
Price to book
2.78
Price to tangible book (TTM)
2.78
Price to free cash flow (TTM)
-9.569
Free cash flow yield (TTM)
-10.45%
Free cash flow per share (TTM)
-68.24%
Growth
Revenue change (TTM)
15.57%
Earnings per share change (TTM)
-34.90%
3-year revenue growth (CAGR)
2.39%
3-year earnings per share growth (CAGR)
-12.32%
What the Analysts think about Personalis
Analyst ratings (Buy, Hold, Sell) for Personalis stock.
Bulls say / Bears say
Personalis' NeXT Personal assay achieved a 100% detection rate of colorectal cancer relapses ahead of traditional imaging methods, demonstrating its potential to revolutionize cancer monitoring and treatment. (businesswire.com)
The company reported a 6% year-over-year increase in Q1 2025 revenue to $20.6 million, with a significant 39% growth in pharma tests and services revenue, indicating strong demand for its offerings. (businesswire.com)
Analysts have raised the price target for Personalis to $9.00, reflecting confidence in the company's growth prospects and potential for stock appreciation. (etfdailynews.com)
Personalis reported a net loss of $15.8 million ($0.18 per share) in Q1 2025, highlighting ongoing profitability challenges. (businesswire.com)
The company's population sequencing revenue decreased by 29% to $6.7 million in Q1 2025, indicating potential volatility in this segment. (businesswire.com)
Despite recent stock price increases, Personalis' price-to-sales ratio of 4.4x is higher than nearly half of its industry peers, suggesting the stock may be overvalued. (simplywall.st)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
Personalis Financial Performance
Revenues and expenses
Personalis Earnings Performance
Company profitability
Personalis News
AllArticlesVideos
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
Business Wire·4 weeks ago
Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study
Business Wire·2 months ago
Personalis to Announce First Quarter 2025 Financial Results
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Personalis stock?
Personalis (PSNL) has a market cap of $577M as of June 19, 2025.
What is the P/E ratio for Personalis stock?
The price to earnings (P/E) ratio for Personalis (PSNL) stock is 0 as of June 19, 2025.
Does Personalis stock pay dividends?
No, Personalis (PSNL) stock does not pay dividends to its shareholders as of June 19, 2025.
When is the next Personalis dividend payment date?
Personalis (PSNL) stock does not pay dividends to its shareholders.
What is the beta indicator for Personalis?
Personalis (PSNL) has a beta rating of 1.87. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.